


The Claims are:

1. (cancelled) A compound of Formula (I):



or a pharmaceutically acceptable salt thereof, wherein:

Q is an aryl, a 5- or 6-membered heteroaryl, or a 4–8-membered heterocyclic ring;

T together with the  $-\text{N}=\text{C}-$  to which it is attached forms a heteroaryl ring, or a heterocyclic ring where the  $\text{N}=\text{C}$  bond is the only site of unsaturation;

$\text{R}^1$  and  $\text{R}^2$  each independently are hydrogen, hydroxy, halogen, cyano, nitro, vinyl, ethynyl, methoxy,  $\text{OCF}_n\text{H}_{3-n}$ ,  $-\text{N}(\text{C}_0\text{-alkyl})(\text{C}_0\text{-alkyl})$ , CHO, or  $\text{C}_{1-2}\text{alkyl}$  optionally substituted with 1-5 independent halogen, hydroxy, cyano, methoxy,  $-\text{N}(\text{C}_0\text{-alkyl})(\text{C}_0\text{-alkyl})$ ,  $\text{SOCH}_3$ , or  $\text{SO}_2\text{CH}_3$  substituents; or  $\text{R}^1$  and  $\text{R}^2$  together form a carbocyclic or heterocyclic ring; or  $\text{R}^1$  and  $\text{R}^2$  may be taken together to represent an oxygen atom attached to the ring via a double bond;

$\text{R}^3$  and  $\text{R}^4$  each independently are hydrogen, halogen,  $\text{OCF}_n\text{H}_{3-n}$ , methoxy,  $\text{CO}_2\text{R}^{77}$ , cyano, nitro, CHO,  $\text{CONR}^{99}\text{R}^{100}$ ,  $\text{CON}(\text{OCH}_3)\text{CH}_3$ , or  $\text{C}_{1-2}\text{alkyl}$ , heteroaryl, or  $\text{C}_{3-7}\text{cycloalkyl}$  optionally substituted with 1-5 independent halogen, hydroxy, cyano, methoxy,  $-\text{NHCO}_2\text{CH}_3$ , or  $-\text{N}(\text{C}_0\text{-alkyl})(\text{C}_0\text{-alkyl})$  substituents; or  $\text{R}^3$  and  $\text{R}^4$  together form a 5–8-membered aromatic, heteroaromatic, carbocyclic, or heterocyclic ring;

$\text{R}^5$  and  $\text{R}^6$  each independently are hydrogen, hydroxy, halogen, cyano, nitro,  $\text{CO}_2\text{R}^7$ , CHO,  $\text{COR}^8$ ,  $\text{C}(\text{OH})\text{R}^7\text{R}^8$ ,  $\text{C}(\text{=NOR}^7)\text{R}^8$ ,  $\text{CONR}^9\text{R}^{10}$ ,  $\text{SR}^7$ ,  $\text{SOR}^8$ ,  $\text{SO}_2\text{R}^8$ ,

$\text{SO}_2\text{NR}^9\text{R}^{10}$ ,  $\text{CH}_2\text{NR}^9\text{R}^{10}$ ,  $\text{NR}^9\text{R}^{10}$ ,  $\text{N}(\text{C}_{0-4}\text{alkyl})\text{SO}_2\text{R}^8$ ,  $\text{NHCOR}^7$ , or  $\text{C}_{1-4}\text{alkyl}$  group,  $\text{C}_{2-4}\text{alkenyl}$  group,  $\text{C}_{2-4}\text{alkynyl}$  group,  $\text{C}_{1-4}\text{alkoxy}$  group, aryl group, or heteroaryl group, wherein any group optionally is substituted with 1-6 independent halogen, cyano, nitro, hydroxy,  $\text{C}_{1-2}\text{alkoxy}$ ,  $-\text{N}(\text{C}_{0-2}\text{alkyl})(\text{C}_{0-2}\text{alkyl})$ ,  $\text{C}_{1-2}\text{alkyl}$ ,  $\text{CF}_n\text{H}_{3-n}$ , aryl, heteroaryl,  $-\text{COC}_{1-2}\text{alkyl}$ ,  $-\text{CON}(\text{C}_{0-2}\text{alkyl})(\text{C}_{0-2}\text{alkyl})$ ,  $\text{SCH}_3$ ,  $\text{SOCH}_3$ ,  $\text{SO}_2\text{CH}_3$ , or  $-\text{SO}_2\text{N}(\text{C}_{0-2}\text{alkyl})(\text{C}_{0-2}\text{alkyl})$  substituents; or  $\text{R}^5$  and  $\text{R}^6$  together form a 5-8-membered carbocyclic or heterocyclic ring;

$\text{R}^7$  and  $\text{R}^{77}$  each independently are hydrogen, or  $\text{C}_{1-4}\text{alkyl}$  group,  $\text{C}_{2-4}\text{alkenyl}$  group,  $\text{C}_{2-4}\text{alkynyl}$  group,  $\text{C}_{3-7}\text{cycloalkyl}$  group, aryl group, heteroaryl group, or 4-7-membered heterocyclic group, wherein any group optionally is substituted with 1-6 independent halogen, cyano, nitro, hydroxy,  $\text{C}_{1-2}\text{alkoxy}$ ,  $-\text{N}(\text{C}_{0-2}\text{alkyl})(\text{C}_{0-2}\text{alkyl})$ ,  $\text{C}_{1-2}\text{alkyl}$ ,  $\text{C}_{3-7}\text{cycloalkyl}$ , 4-7-membered heterocyclic ring,  $\text{CF}_n\text{H}_{3-n}$ , aryl, heteroaryl,  $\text{CO}_2\text{H}$ ,  $-\text{COC}_{1-2}\text{alkyl}$ ,  $-\text{CON}(\text{C}_{0-2}\text{alkyl})(\text{C}_{0-2}\text{alkyl})$ ,  $\text{SOCH}_3$ ,  $\text{SO}_2\text{CH}_3$ , or  $-\text{SO}_2\text{N}(\text{C}_{0-2}\text{alkyl})(\text{C}_{0-2}\text{alkyl})$  substituents;

$\text{R}^8$  is  $\text{C}_{1-4}\text{alkyl}$  group,  $\text{C}_{2-4}\text{alkenyl}$  group,  $\text{C}_{2-4}\text{alkynyl}$  group,  $\text{C}_{3-7}\text{cycloalkyl}$  group, aryl group, heteroaryl group, or 4-7-membered heterocyclic group, wherein any group optionally is substituted with 1-6 independent halogen, cyano, nitro, hydroxy,  $\text{C}_{1-2}\text{alkoxy}$ ,  $-\text{N}(\text{C}_{0-2}\text{alkyl})(\text{C}_{0-2}\text{alkyl})$ ,  $\text{C}_{1-2}\text{alkyl}$ ,  $\text{C}_{3-7}\text{cycloalkyl}$ , 4-7-membered heterocyclic ring,  $\text{CF}_n\text{H}_{3-n}$ , aryl, heteroaryl,  $\text{CO}_2\text{H}$ ,  $\text{COC}_{1-2}\text{alkyl}$ ,  $-\text{CON}(\text{C}_{0-2}\text{alkyl})(\text{C}_{0-2}\text{alkyl})$ ,  $\text{SOCH}_3$ ,  $\text{SO}_2\text{CH}_3$ , or  $-\text{SO}_2\text{N}(\text{C}_{0-2}\text{alkyl})(\text{C}_{0-2}\text{alkyl})$  substituents;

$\text{R}^9$ ,  $\text{R}^{10}$ ,  $\text{R}^{99}$ , and  $\text{R}^{100}$  each independently are hydrogen, or  $\text{C}_{1-4}\text{alkyl}$  group,  $\text{C}_{3-7}\text{cycloalkyl}$  group, aryl group, heteroaryl group, or 4-7-membered heterocyclic group, wherein any group optionally is substituted with 1-6 independent halogen, cyano, nitro, hydroxy,  $\text{C}_{1-2}\text{alkoxy}$ ,  $-\text{N}(\text{C}_{0-2}\text{alkyl})(\text{C}_{0-2}\text{alkyl})$ ,  $\text{C}_{1-2}\text{alkyl}$ ,  $\text{C}_{3-7}\text{cycloalkyl}$ , 4-7-membered heterocyclic ring,  $\text{CF}_n\text{H}_{3-n}$ , aryl, heteroaryl,  $\text{COC}_{1-2}\text{alkyl}$ ,  $-\text{CON}(\text{C}_{0-2}\text{alkyl})(\text{C}_{0-2}\text{alkyl})$ ,  $\text{SOCH}_3$ ,  $\text{SO}_2\text{CH}_3$ , or  $-\text{SO}_2\text{N}(\text{C}_{0-2}\text{alkyl})(\text{C}_{0-2}\text{alkyl})$  substituents; or  $\text{R}^9$  and  $\text{R}^{10}$  or  $\text{R}^{99}$  and  $\text{R}^{100}$  together form a 6-8-membered heterobicyclic ring system or a 4-8-membered heterocyclic ring which optionally is substituted with 1-2 independent  $\text{C}_{1-2}\text{alkyl}$ ,  $\text{CH}_2\text{OCH}_3$ ,  $\text{COC}_{0-2}\text{alkyl}$ , hydroxy, or  $\text{SO}_2\text{CH}_3$  substituents;

n is 1, 2 or 3;

m is 0 or 1; and

the dotted line together with the solid line forms an optional double bond, and  $\Delta$  indicates that the double bond has the (E)-configuration.

2. (cancelled) A compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein the dotted line together with the solid line forms a double bond.

3. (cancelled) A compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein the dotted line together with the solid line forms a single bond.


4. (cancelled) A compound according to claim 3, or a pharmaceutically acceptable salt thereof, wherein the dotted line together with the solid line forms a single bond, and the absolute configuration at the asymmetric centre  $\alpha$  to the amide carbonyl carbon is (R).

5. (cancelled) A compound according to claim 1, wherein m is 0.

6. (cancelled) The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein Q is thienyl, furyl, thiazolyl, pyridyl, tetrahydropyranyl, piperidinyl, tetrahydrothiopyranyl, 1-oxo-tetrahydrothiopyranyl or 1,1-dioxo-tetrahydrothiopyranyl.


7. (cancelled) A compound according to claim 6, or a pharmaceutically acceptable salt thereof, wherein Q is 4-tetrahydropyranyl.

8. (cancelled) The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein the group of formula




is thiazolyl, thiadiazolyl, oxazolyl, isoxazolyl, pyrimidinyl, pyrazinyl, or pyridyl.

9. (cancelled) A compound according to claim 8, or a pharmaceutically acceptable salt thereof, wherein the group of formula



is 2-pyrazinyl or 2-thiazolyl.

10. (cancelled) A compound according to claim 9, or a pharmaceutically acceptable salt thereof, wherein the group of formula



is 2-thiazolyl, R<sup>3</sup> is 5-fluoro and R<sup>4</sup> is hydrogen.

11. (cancelled) A compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R<sup>3</sup> and R<sup>4</sup> are independently selected from hydrogen, halogen, and methyl.

12. (cancelled) A compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R<sup>5</sup> is SOR<sup>8</sup>, SO<sub>2</sub>R<sup>8</sup>, or SO<sub>2</sub>NR<sup>9</sup>R<sup>10</sup>.

13. (cancelled) A compound according to claim 12, or a pharmaceutically acceptable salt thereof, wherein R<sup>8</sup> is C<sub>1-4</sub>alkyl or C<sub>3-7</sub>cycloalkyl.

14. (cancelled) A compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R<sup>5</sup> is SO<sub>2</sub>C<sub>3-4</sub>cycloalkyl.

15. (cancelled) A compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R<sup>6</sup> is hydrogen.

16. (cancelled) A compound selected from:

(E)-2-(4-Methanesulfonylphenyl)-N-thiazol-2-yl-3-thiophen-3-ylacrylamide;

(E)-2-(4-Methanesulfonylphenyl)-N-thiazol-2-yl-3-thiophen-2-ylacrylamide;

(E)-3-Furan-2-yl-2-(4-methanesulfonylphenyl)-N-thiazol-2-ylacrylamide;

(E)-2-(4-Methanesulfonylphenyl)-3,N-bisthiazol-2-ylacrylamide;

(E)-2-(4-Methanesulfonylphenyl)-3-(5-methylthiophen-2-yl)-N-thiazol-2-ylacrylamide;

(E)-3-(5-Chlorothiophen-2-yl)-2-(4-methanesulfonylphenyl)-N-thiazol-2-ylacrylamide;

(E)-2-(4-Methanesulfonylphenyl)-3-thiazol-5-yl-N-thiazol-2-ylacrylamide;

2-(4-Methanesulfonylphenyl)-N-thiazol-2-yl-3-thiophen-2-ylpropionamide;

2-(4-Cyclopropanesulfonylphenyl)-3-(tetrahydropyran-4-yl)-N-thiazol-2-ylpropionamide;

2-(4-Cyclopropanesulfonylphenyl)-N-(5-fluorothiazol-2-yl)-3-(tetrahydropyran-4-yl)propionamide;

N-(5-Fluorothiazol-2-yl)-2-(4-methanesulfonylphenyl)-3-(tetrahydropyran-4-yl)propionamide;

(E)-2-(4-Bromophenyl)-3-(tetrahydropyran-4-yl)-N-thiazol-2-ylacrylamide;

(E)-2-(4-Methoxyphenyl)-3-(tetrahydropyran-4-yl)-N-thiazol-2-ylacrylamide;

(E)-3-(Tetrahydropyran-4-yl)-N-thiazol-2-yl-2-(4-[1,2,4]triazol-1-ylphenyl)acrylamide;

(E)-3-(Tetrahydrothiopyran-4-yl)-N-thiazol-2-yl-2-(4-[1,2,4]triazol-1-ylphenyl)acrylamide;

(*E*)-3-(Tetrahydropyran-4-yl)-*N*-thiazol-2-yl-2-(4-[1,2,3]triazol-1-ylphenyl)acrylamide;

3-(Tetrahydropyran-4-yl)-*N*-thiazol-2-yl-2-(4-trifluoromethylsulfanylphenyl)propionamide;

2-(4-Methylsulfanyl methylphenyl)-3-(tetrahydropyran-4-yl)propionamide;

2-(4-Methanesulfonylphenyl)-*N*-(1*H*-pyrazol-3-yl)-3-(tetrahydropyran-4-yl)propionamide;

2-(4-Methanesulfonylphenyl)-*N*-pyridin-2-yl-3-(tetrahydropyran-4-yl)propionamide;

2-(4-Methanesulfonylphenyl)-*N*-pyrimidin-4-yl-3-(tetrahydropyran-4-yl)propionamide;

*N*-(4,5-Dihydrothiazol-2-yl)-2-(4-methanesulfonylphenyl)-3-(tetrahydropyran-4-yl)propionamide;

*N*-(1*H*-Imidazol-2-yl)-2-(4-methanesulfonylphenyl)-3-(tetrahydropyran-4-yl)propionamide;

*N*-Benzothiazol-2-yl-2-(4-methanesulfonylphenyl)-3-(tetrahydropyran-4-yl)propionamide;

2-(4-Methanesulfonylphenyl)-3-(tetrahydropyran-4-yl)-*N*-[1,3,4]thiadiazol-2-ylpropionamide;

2-(4-Methanesulfonylphenyl)-*N*-(3-methyl-[1,2,4]thiadiazol-5-yl)-3-(tetrahydropyran-4-yl)propionamide;

*N*-(5-Fluoropyridin-2-yl)-2-(4-methanesulfonylphenyl)-3-(tetrahydropyran-4-yl)propionamide;

2-(4-Methanesulfonylphenyl)-*N*-pyrazin-2-yl-3-(tetrahydropyran-4-yl)propionamide;

2-(4-Methanesulfonylphenyl)-*N*-(5-methylthiazol-2-yl)-3-(tetrahydropyran-4-yl)propionamide;

2-(4-Methanesulfonylphenyl)-*N*-(4-methylthiazol-2-yl)-3-(tetrahydropyran-4-yl)propionamide;

2-(4-Cyclopropanesulfonylphenyl)-*N*-(3-methyl-[1,2,4]thiadiazol-5-yl)-3-(tetrahydropyran-4-yl)propionamide;

2-(4-Cyclopropanesulfonylphenyl)-*N*-pyrazin-2-yl-3-(tetrahydropyran-4-yl)propionamide;

2-(4-Cyclopropanesulfonylphenyl)-3-(tetrahydropyran-4-yl)-*N*-[1,2,4]thiadiazol-5-ylpropionamide;

(*E*)-2-(4-Cyclopropanesulfonylphenyl)-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylacrylamide;

2-(4-Methanesulfonylphenyl)-*N*-(5-nitrothiazol-2-yl)-3-(tetrahydropyran-4-yl)propionamide;

(*E*)-*N*-(5-Chlorothiazol-2-yl)-2-(4-methanesulfonylphenyl)-3-thiophen-2-ylacrylamide;

(*E*)-*N*-(5-Chloro-4-methylthiazol-2-yl)-2-(4-methanesulfonylphenyl)-3-thiophen-2-ylacrylamide;

(*E*)-*N*-(5-Chlorothiazol-2-yl)-3-furan-2-yl-2-(4-methanesulfonylphenyl)acrylamide;

(*E*)-*N*-(5-Chlorothiazol-2-yl)-2-(4-methanesulfonylphenyl)-3-thiophen-3-ylacrylamide;

(*E*)-*N*-(5-Chlorothiazol-2-yl)-2-(4-methanesulfonylphenyl)-3-pyridin-3-ylacrylamide;

*N*-(5-Chlorothiazol-2-yl)-2-(4-methanesulfonylphenyl)-3-thiophen-2-ylpropionamide;

*N*-(5-Chloro-4-methylthiazol-2-yl)-2-(4-methanesulfonylphenyl)-3-(tetrahydropyran-4-yl)propionamide;

(*E*)-*N*-(5-Chlorothiazol-2-yl)-2-(4-methanesulfonylphenyl)-3-thiazol-5-ylacrylamide;

(*E*)-2-(4-Bromophenyl)-*N*-(5-chlorothiazol-2-yl)-3-furan-2-ylacrylamide;

(*E*)-2-(4-Bromophenyl)-3-furan-2-yl-*N*-pyrimidin-4-ylacrylamide;

(*E*)-2-(4-Bromophenyl)-*N*-(5-bromothiazol-2-yl)-3-furan-2-ylacrylamide;

(*E*)-2-(4-Bromophenyl)-3-furan-2-yl-*N*-thiazol-2-ylacrylamide;

(*E*)-2-(4-Bromophenyl)-3-furan-2-yl-*N*-(5-methylthiazol-2-yl)acrylamide;  
(*E*)-*N*-Benzothiazol-2-yl-2-(4-bromophenyl)-3-furan-2-ylacrylamide;  
(*E*)-2-(4-Bromophenyl)-*N*-(4,5-dimethylthiazol-2-yl)-3-furan-2-ylacrylamide;  
(*E*)-2-(4-Bromophenyl)-*N*-(5-bromothiazol-2-yl)-3-thiophen-2-ylacrylamide;  
(*E*)-2-(4-Bromophenyl)-*N*-thiazol-2-yl-3-thiophen-2-ylacrylamide;  
(*E*)-2-(4-Bromophenyl)-*N*-[1,3,4]thiadiazol-2-yl-3-thiophen-2-ylacrylamide;  
(*E*)-2-(4-Bromophenyl)-*N*-(5-methylthiazol-2-yl)-3-thiophen-2-ylacrylamide;  
(*E*)-2-(4-Bromophenyl)-*N*-(5-chlorothiazol-2-yl)-3-thiophen-2-ylacrylamide;  
(*E*)-3-Furan-2-yl-2-(4-methoxyphenyl)-*N*-thiazol-2-ylacrylamide;  
(*E*)-3-Furan-2-yl-2-(4-methoxyphenyl)-*N*-(5-methylthiazol-2-yl)acrylamide;  
(*E*)-*N*-(5-Chlorothiazol-2-yl)-2-(4-nitrophenyl)-3-thiophen-2-ylacrylamide;  
(*E*)-*N*-(5-Bromothiazol-2-yl)-2-(4-nitrophenyl)-3-thiophen-2-ylacrylamide;  
(*E*)-2-(4-Nitrophenyl)-*N*-thiazol-2-yl-3-thiophen-2-ylacrylamide;  
(*E*)-*N*-(5-Bromothiazol-2-yl)-2-(4-methanesulfonylphenyl)-3-thiophen-2-ylacrylamide;  
(*E*)-2-(4-Cyanophenyl)-*N*-thiazol-2-yl-3-thiophen-2-ylacrylamide;  
(*E*)-*N*-(5-Chlorothiazol-2-yl)-2-(4-cyanophenyl)-3-thiophen-2-ylacrylamide;  
(*E*)-*N*-(5-Chlorothiazol-2-yl)-2-(4-cyanophenyl)-3-phenylacrylamide;  
2-(4-Methanesulfonylphenyl)-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-yl-propionamide;  
(*E*)-2-Phenyl-*N*-thiazol-2-yl-3-thiophen-2-ylacrylamide;  
(*E*)-2-Phenyl-*N*-[1,3,4]thiadiazol-2-yl-3-thiophen-2-ylacrylamide;  
(*E*)-2-(4-Methanesulfonylphenyl)-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylacrylamide;  
(*E*)-*N*-(5-Chlorothiazol-2-yl)-2-(4-methanesulfonylphenyl)-3-(tetrahydropyran-4-yl)acrylamide;  
(*E*)-*N*-(5-Bromothiazol-2-yl)-2-(4-methanesulfonylphenyl)-3-(tetrahydropyran-4-yl)acrylamide;  
(*E*)-2-(4-Methanesulfonylphenyl)-3-(tetrahydrothiopyran-4-yl)-*N*-thiazol-2-ylacrylamide;

(*E*)-*N*-(5-Chlorothiazol-2-yl)-2-(4-methanesulfonylphenyl)-3-(tetrahydrothiopyran-4-yl)acrylamide;

(*E*)-*N*-(5-Chloro-4-methylthiazol-2-yl)-2-(4-methanesulfonylphenyl)-3-(tetrahydrothiopyran-4-yl)acrylamide;

(*E*)-2-(4-Methanesulfinylphenyl)-3-(tetrahydrothiopyran-4-yl)-*N*-thiazol-2-ylacrylamide;

(*E*)-*N*-(5-Chlorothiazol-2-yl)-2-(4-methanesulfinylphenyl)-3-(tetrahydrothiopyran-4-yl)acrylamide;

*N*-(5-Chlorothiazol-2-yl)-2-(4-methanesulfonylphenyl)-3-(tetrahydropyran-4-yl)propionamide;

2-(4-Methoxymethylsulfonylphenyl)-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

3-(Tetrahydropyran-4-yl)-2-[4-(tetrahydropyran-4-ylsulfanyl)phenyl]-*N*-thiazol-2-ylpropionamide;

2-(3-Methylsulfonylphenyl)-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-(4-Methylsulfonyl-3-nitrophenyl)-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

(*E*)-2-(4-Nitrophenyl)-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylacrylamide;

(*E*)-*N*-(5-Chlorothiazol-2-yl)-2-(4-nitrophenyl)-3-(tetrahydropyran-4-yl)acrylamide;

(*E*)-2-(4-Methylsulfonylphenyl)-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylacrylamide;

(*E*)-*N*-(5-Chlorothiazol-2-yl)-2-(4-methylsulfonylphenyl)-3-(tetrahydropyran-4-yl)acrylamide;

2-(3-Fluoro-4-methylsulfonylphenyl)-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-(4-Cyclopropanesulfonylphenyl)-*N*-(5-formylthiazol-2-yl)-3-(tetrahydropyran-4-yl)propionamide;

(*E*)-*N*-(5-Chlorothiazol-2-yl)-2-(4-cyclopropanesulfinylphenyl)-3-(tetrahydropyran-4-yl)acrylamide;

(*E*)-2-(4-Cyclopropanesulfinylphenyl)-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylacrylamide;

2-(3-Bromo-4-methanesulfonylphenyl)-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-(4-Ethanesulfonylphenyl)-*N*-(3-methyl-[1,2,4]thiadiazol-5-yl)-3-(tetrahydropyran-4-yl)propionamide;

2-(4-Ethylsulfamoylphenyl)-*N*-pyrimidin-4-yl-3-(tetrahydropyran-4-yl)propionamide;

2-(4-Ethylsulfamoylphenyl)-*N*-pyrazin-2-yl-3-(tetrahydropyran-4-yl)propionamide

(2*R*)-3-(Tetrahydropyran-4-yl)-2-(4-methanesulfonylphenyl)-*N*-thiazol-2-ylpropionamide;

(2*R*)-2-(4-Cyclopropanesulfonylphenyl)-*N*-(5-fluorothiazol-2-yl)-3-(tetrahydropyran-4-yl)propionamide;

(2*R*)-*N*-(5-Chlorothiazol-2-yl)-2-(4-methanesulfonylphenyl)-3-(tetrahydropyran-4-yl)propionamide;

(2*R*)-*N*-(5-Fluorothiazol-2-yl)-2-(4-methanesulfonylphenyl)-3-(tetrahydropyran-4-yl)propionamide;

(2*R*)-2-(4-Cyclopropanesulfonylphenyl)-3-(tetrahydropyran-4-yl)-*N*-[1,2,4]thiadiazol-5-ylpropionamide;

(2*R*)-2-(4-Cyclopropanesulfonylphenyl)-*N*-pyrazin-2-yl-3-(tetrahydropyran-4-yl)propionamide;

(2*R*)-*N*-(5-Fluoropyridin-2-yl)-2-(4-methanesulfonylphenyl)-3-(tetrahydropyran-4-yl)propionamide;

(2*R*)-2-(4-Cyclopropanesulfonylphenyl)-*N*-(5-fluoropyridin-2-yl)-3-(tetrahydropyran-4-yl)propionamide;

(2*R*)-2-(4-Cyclopropanesulfonylphenyl)-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

(2*R*)-2-(4-Cyclopropanesulfonylphenyl)-*N*-(3-methyl-[1,2,4]thiadiazol-5-yl)-3-(tetrahydropyran-4-yl)propionamide;

(2*R*)-2-(4-Cyclobutanesulfonylphenyl)-*N*-pyrazin-2-yl-3-(tetrahydropyran-4-yl)propionamide;

(2*R*)-2-(4-Cyclobutanesulfonylphenyl)-*N*-pyrimidin-4-yl-3-(tetrahydropyran-4-yl)propionamide;

(2*R*)-2-(4-Cyclobutanesulfonylphenyl)-*N*-isoxazol-3-yl-3-(tetrahydropyran-4-yl)propionamide;

(2*R*)-2-(4-Cyclobutanesulfonylphenyl)-*N*-(1-methyl-1*H*-pyrazol-3-yl)-3-(tetrahydropyran-4-yl)propionamide;

(2*R*)-2-(4-Cyclobutanesulfonylphenyl)-*N*-(5-fluorothiazol-2-yl)-3-(tetrahydropyran-4-yl)propionamide;

(2*R*)-2-(4-Ethylsulfamoylphenyl)-*N*-pyrazin-2-yl-3-(tetrahydropyran-4-yl)-propionamide;

(2*R*)-2-(4-Ethylsulfamoylphenyl)-*N*-pyrimidin-4-yl-3-(tetrahydropyran-4-yl)-propionamide;

(2*R*)-2-(4-Ethylsulfamoylphenyl)-*N*-pyridin-2-yl-3-(tetrahydropyran-4-yl)-propionamide;

(2*R*)-2-(4-Ethylsulfamoylphenyl)-*N*-(1-methyl-1*H*-pyrazol-3-yl)-3-(tetrahydropyran-4-yl)propionamide;

(2*R*)-2-(4-Ethylsulfamoylphenyl)-*N*-(3-methyl-[1,2,4]thiadiazol-5-yl)-3-(tetrahydropyran-4-yl)propionamide;

(2*R*)-2-(4-Ethylsulfamoylphenyl)-*N*-(6-methoxypyrimidin-4-yl)-3-(tetrahydropyran-4-yl)propionamide;

(*E*)-2-(4-Cyclopropanesulfonylphenyl)-*N*-(5-fluoropyridin-2-yl)-3-(tetrahydropyran-4-yl)acrylamide;

(*E*)-2-(4-Cyclopropanesulfonylphenyl)-*N*-(5-fluorothiazol-2-yl)-3-(tetrahydropyran-4-yl)acrylamide;

2-(3-Fluoro-4-methanesulfonylphenyl)-*N*-(5-fluorothiazol-2-yl)-3-(tetrahydropyran-4-yl)propionamide;

(*E*)-*N*-(5-Fluorothiazol-2-yl)-2-(4-methanesulfonylphenyl)-3-(tetrahydropyran-4-yl)acrylamide;

(*E*)-2-(4-Ethanesulfonylphenyl)-*N*-pyrimidin-4-yl-3-(tetrahydropyran-4-yl)acrylamide;

(*E*)-2-(4-Ethanesulfonylphenyl)-*N*-isoxazol-3-yl-3-(tetrahydropyran-4-yl)acrylamide;

(*E*)-*N*-(5-Fluorothiazol-2-yl)-2-[4-(propane-1-sulfonyl)phenyl]-3-(tetrahydropyran-4-yl)acrylamide;

(*E*)-2-[4-(Propane-1-sulfonyl)phenyl]-*N*-pyrimidin-4-yl-3-(tetrahydropyran-4-yl)acrylamide;

(*E*)-*N*-(3-Methyl-[1,2,4]thiadiazol-5-yl)-2-[4-(propane-1-sulfonyl)phenyl]-3-(tetrahydropyran-4-yl)acrylamide;

(*E*)-*N*-(1-Methyl-1*H*-pyrazol-3-yl)-2-[4-(propane-1-sulfonyl)phenyl]-3-(tetrahydropyran-4-yl)acrylamide;

(*E*)-2-Phenyl-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylacrylamide;

(*E*)-2-(4-Formylphenyl)-*N*-(5-formylthiazol-2-yl)-3-(tetrahydropyran-4-yl)acrylamide;

(*E*)-*N*-(5-Formylthiazol-2-yl)-2-phenyl-3-(tetrahydropyran-4-yl)acrylamide;

2-[2-(4-Methanesulfonylphenyl)-3-(tetrahydropyran-4-yl)propionylamino]thiazole-5-carboxylic acid;

2-[2-(4-Methanesulfonylphenyl)-3-(tetrahydropyran-4-yl)propionylamino]thiazole-5-carboxylic acid methoxy-methyl-amide;

2-[2-(4-Methanesulfonylphenyl)-3-(tetrahydropyran-4-yl)propionylamino]thiazole-5-carboxylic acid methylamide;

(*E*)-2-[2-(4-Methanesulfonylphenyl)-3-(tetrahydropyran-4-yl)acryloylamino]thiazole-5-carboxylic acid methylamide;

*N*-(5-Formylthiazol-2-yl)-2-(4-methanesulfonylphenyl)-3-(tetrahydropyran-4-yl)propionamide;

*N*-(5-Hydroxymethylthiazol-2-yl)-2-(4-methanesulfonylphenyl)-3-(tetrahydropyran-4-yl)propionamide;

*N*-(5-Cyanothiazol-2-yl)-2-(4-cyclopropanesulfonylphenyl)-3-(tetrahydropyran-4-yl)propionamide;

*N*-(5-Cyanothiazol-2-yl)-2-(4-methanesulfonylphenyl)-3-(tetrahydropyran-4-yl)propionamide;

Methyl {2-[2-(4-methanesulfonylphenyl)-3-(tetrahydropyran-4-yl)propionylamino]-thiazol-5-ylmethyl} carbamate;

(*E*)-3-(1-Formylpiperidin-4-yl)-2-(4-methanesulfonylphenyl)-*N*-thiazol-2-ylacrylamide;

(*E*)-2-(4-Methanesulfonylphenyl)-3-(1-oxohexahydro-1 $\lambda^4$ -thiopyran-4-yl)-*N*-thiazol-2-ylacrylamide;

(*E*)-3-(1,1-Dioxohexahydro-1 $\lambda^6$ -thiopyran-4-yl)-2-(4-methanesulfonylphenyl)-*N*-thiazol-2-ylacrylamide;

(*E*)-*N*-(5-Chlorothiazol-2-yl)-2-(4-methanesulfonylphenyl)-3-(1-oxohexahydro-1 $\lambda^4$ -thiopyran-4-yl)acrylamide;

(*E*)-*N*-(5-Chlorothiazol-2-yl)-3-(1,1-dioxohexahydro-1 $\lambda^6$ -thiopyran-4-yl)-2-(4-methanesulfonylphenyl)acrylamide;

2-(3-Fluoro-4-methanesulfinylphenyl)-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-(3-Fluoro-4-methanesulfonylphenyl)-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

*N*-(5-Bromothiazol-2-yl)-2-(4-methanesulfonylphenyl)-3-(tetrahydropyran-4-yl)propionamide;

(*E*)-2-(4-Hydroxyphenyl)-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylacrylamide;

(*E*)-2-(4-Methanesulfonylaminophenyl)-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylacrylamide;

3-(Tetrahydropyran-4-yl)-2-[4-(tetrahydropyran-4-ylmethylsulfanyl)phenyl]-*N*-thiazol-2-ylpropionamide;

2-[4-(Pyridin-3-ylsulfanyl)phenyl]-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

3-(Tetrahydropyran-4-yl)-2-[4-(tetrahydropyran-4-ylmethanesulfonyl)phenyl]-*N*-thiazol-2-ylpropionamide;

2-(4-Methoxymethanesulfonylphenyl)-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-[4-(Tetrahydropyran-4-sulfonyl)phenyl]-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-[4-(Pyridine-3-sulfonyl)phenyl]-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-(3-Methanesulfonylphenyl)-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-(4-Cyclopropylmethanesulfonylphenyl)-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-[4-(Pyridin-3-ylmethanesulfonyl)phenyl]-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-[4-(Propane-1-sulfonyl)phenyl]-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-(4-Ethanesulfonylphenyl)-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-(4-Cyanomethanesulfonylphenyl)-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-[4-([1,2,4]Oxadiazol-3-ylmethanesulfonyl)phenyl]-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-[4-([1,3]Dioxolan-2-ylmethanesulfonyl)phenyl]-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-[4-(Propane-2-sulfonyl)phenyl]-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-[4-(Oxetane-3-sulfonyl)phenyl]-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-[4-((3*S*)-Tetrahydrofuran-3-sulfonyl)phenyl]-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-[4-((3*R*)-Tetrahydrofuran-3-sulfonyl)phenyl]-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-(4-Cyclobutanesulfonylphenyl)-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-[4-(2-Oxopropane-1-sulfonyl)phenyl]-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-[4-(Pyridine-2-sulfonyl)phenyl]-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-[4-(Pyridine-2-sulfinyl)phenyl]-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-[4-(Pyrazine-2-sulfonyl)phenyl]-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-[4-(Pyrazine-2-sulfinyl)phenyl]-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-[4-(Pyrimidine-5-sulfonyl)phenyl]-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-(3-Amino-4-methanesulfonylphenyl)-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-(3-Chloro-4-methanesulfonylphenyl)-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-[4-(Morpholine-4-sulfonyl)phenyl]-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-(4-Sulfamoylphenyl)-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-(4-Methylsulfamoylphenyl)-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-(4-Dimethylsulfamoylphenyl)-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-[4-(4-Methylpiperazine-1-sulfonyl)phenyl]-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-{4-[(Pyridin-2-ylmethyl)sulfamoyl]phenyl}-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-{4-[(Pyridin-3-ylmethyl)sulfamoyl]phenyl}-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

3-(Tetrahydropyran-4-yl)-2-{4-[(tetrahydropyran-4-ylmethyl)sulfamoyl]phenyl}-*N*-thiazol-2-ylpropionamide;

2-{4-[(Tetrahydrofuran-2-ylmethyl)sulfamoyl]phenyl}-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

3-(Tetrahydropyran-4-yl)-*N*-thiazol-2-yl-2-[4-(thiomorpholine-4-sulfonyl)phenyl]propionamide;

2-[4-(Azetidine-1-sulfonyl)phenyl]-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-[4-([1,4]Oxazepane-4-sulfonyl)phenyl]-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-(4-Cyclopropylsulfamoylphenyl)-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-[4-(Cyclopropylmethylsulfamoyl)phenyl]-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

3-(Tetrahydropyran-4-yl)-*N*-thiazol-2-yl-2-{4-[(thiophen-2-ylmethyl)sulfamoyl]phenyl}propionamide;

2-[4-((1*S*,4*S*)-2-Oxa-5-azabicyclo[2.2.1]heptane-5-sulfonyl)phenyl]-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-(4-Ethylsulfamoylphenyl)-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-[4-(4-Methyl-[1,4]diazepane-1-sulfonyl)phenyl]-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-[4-((2*R*)-2-Methoxymethylpyrrolidine-1-sulfonyl)phenyl]-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

3-(Tetrahydropyran-4-yl)-2-[4-(tetrahydropyran-4-ylsulfamoyl)phenyl]-*N*-thiazol-2-ylpropionamide;

2-[4-(Imidazole-1-sulfonyl)phenyl]-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

*N*-(5-Chlorothiazol-2-yl)-2-[4-(2-dimethylaminoethylsulfamoyl)phenyl]-3-(tetrahydropyran-4-yl)propionamide;

*N*-(5-Chlorothiazol-2-yl)-2-[4-(3-hydroxyazetidine-1-sulfonyl)phenyl]-3-(tetrahydropyran-4-yl)propionamide;

*N*-(5-Chlorothiazol-2-yl)-2-[4-((3*S*)-3-hydroxypyrrolidine-1-sulfonyl)phenyl]-3-(tetrahydropyran-4-yl)propionamide;

*N*-(5-Chlorothiazol-2-yl)-2-[4-(4-methylpiperazine-1-sulfonyl)phenyl]-3-(tetrahydropyran-4-yl)propionamide;

*N*-(5-Chlorothiazol-2-yl)-2-[4-(piperazine-1-sulfonyl)phenyl]-3-(tetrahydropyran-4-yl)propionamide;

*N*-(5-Chlorothiazol-2-yl)-2-[4-(2-methylaminoethylsulfamoyl)phenyl]-3-(tetrahydropyran-4-yl)propionamide;

2-[4-(2-Aminoethylsulfamoyl)phenyl]-*N*-(5-chlorothiazol-2-yl)-3-(tetrahydropyran-4-yl)propionamide;

*N*-Ethyl-4-[2-(tetrahydropyran-4-yl)-1-(thiazol-2-ylcarbamoyl)ethyl]benzamide;

2-(3-Chloro-4-methanesulfonylphenyl)-*N*-(5-fluorothiazol-2-yl)-3-(tetrahydropyran-4-yl)propionamide;

2-(4-Methanesulfonyl-3-trifluoromethylphenyl)-*N*-(5-fluorothiazol-2-yl)-3-(tetrahydropyran-4-yl)propionamide; and

2-(3,4-Dichlorophenyl)-*N*-(5-fluorothiazol-2-yl)-3-(tetrahydropyran-4-yl)propionamide;

or a pharmaceutically acceptable salt thereof.

17. (cancelled) A compound selected from:

(*E*)-2-(4-Methanesulfonylphenyl)-*N*-thiazol-2-yl-3-thiophen-2-ylacrylamide;

(*E*)-3-Furan-2-yl-2-(4-methanesulfonylphenyl)-*N*-thiazol-2-ylacrylamide;

2-(4-Cyclopropanesulfonylphenyl)-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-(4-Cyclopropanesulfonylphenyl)-*N*-(5-fluorothiazol-2-yl)-3-(tetrahydropyran-4-yl)propionamide;

(*E*)-3-(Tetrahydropyran-4-yl)-*N*-thiazol-2-yl-2-(4-[1,2,4]triazol-1-ylphenyl)acrylamide;

(*E*)-3-(Tetrahydrothiopyran-4-yl)-*N*-thiazol-2-yl-2-(4-[1,2,4]triazol-1-ylphenyl)acrylamide;

(*E*)-3-(Tetrahydropyran-4-yl)-*N*-thiazol-2-yl-2-(4-[1,2,3]triazol-1-ylphenyl)acrylamide;

*N*-Benzothiazol-2-yl-2-(4-methanesulfonylphenyl)-3-(tetrahydropyran-4-yl)propionamide;

2-(4-Cyclopropanesulfonylphenyl)-*N*-(3-methyl-[1,2,4]thiadiazol-5-yl)-3-(tetrahydropyran-4-yl)propionamide;

2-(4-Cyclopropanesulfonylphenyl)-*N*-pyrazin-2-yl-3-(tetrahydropyran-4-yl)propionamide;

2-(4-Cyclopropanesulfonylphenyl)-3-(tetrahydropyran-4-yl)-*N*-[1,2,4]thiadiazol-5-ylpropionamide;

(*E*)-2-(4-Cyclopropanesulfonylphenyl)-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylacrylamide;

(*E*)-*N*-(5-Chloro-4-methylthiazol-2-yl)-2-(4-methanesulfonylphenyl)-3-thiophen-2-ylacrylamide;

(*E*)-2-(4-Methanesulfonylphenyl)-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylacrylamide;

(*E*)-*N*-(5-Chlorothiazol-2-yl)-2-(4-methanesulfonylphenyl)-3-(tetrahydropyran-4-yl)acrylamide;

(*E*)-*N*-(5-Bromothiazol-2-yl)-2-(4-methanesulfonylphenyl)-3-(tetrahydropyran-4-yl)acrylamide;

(*E*)-2-(4-Methanesulfonylphenyl)-3-(tetrahydrothiopyran-4-yl)-*N*-thiazol-2-ylacrylamide;

(*E*)-*N*-(5-Chlorothiazol-2-yl)-2-(4-methanesulfonylphenyl)-3-(tetrahydrothiopyran-4-yl)acrylamide;

(*E*)-*N*-(5-Chlorothiazol-2-yl)-2-(4-methanesulfinylphenyl)-3-(tetrahydrothiopyran-4-yl)acrylamide;  
2-(4-Methoxymethylsulfanylphenyl)-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;  
(*E*)-2-(4-Nitrophenyl)-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylacrylamide;  
(*E*)-*N*-(5-Chlorothiazol-2-yl)-2-(4-nitrophenyl)-3-(tetrahydropyran-4-yl)acrylamide;  
(*E*)-2-(4-Methylsulfanylphenyl)-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylacrylamide;  
(*E*)-*N*-(5-Chlorothiazol-2-yl)-2-(4-methylsulfanylphenyl)-3-(tetrahydropyran-4-yl)acrylamide;  
(*E*)-*N*-(5-Chlorothiazol-2-yl)-2-(4-cyclopropanesulfinylphenyl)-3-(tetrahydropyran-4-yl)acrylamide;  
(*E*)-2-(4-Cyclopropanesulfinylphenyl)-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylacrylamide;  
(2*R*)-2-(4-Cyclopropanesulfonylphenyl)-*N*-(5-fluorothiazol-2-yl)-3-(tetrahydropyran-4-yl)propionamide;  
(2*R*)-2-(4-Cyclopropanesulfonylphenyl)-3-(tetrahydropyran-4-yl)-*N*-[1,2,4]thiadiazol-5-ylpropionamide;  
(2*R*)-2-(4-Cyclopropanesulfonylphenyl)-*N*-pyrazin-2-yl-3-(tetrahydropyran-4-yl)propionamide;  
(2*R*)-2-(4-Cyclopropanesulfonylphenyl)-*N*-(5-fluoropyridin-2-yl)-3-(tetrahydropyran-4-yl)propionamide;  
(2*R*)-2-(4-Cyclopropanesulfonylphenyl)-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;  
(2*R*)-2-(4-Cyclopropanesulfonylphenyl)-*N*-(3-methyl-[1,2,4]thiadiazol-5-yl)-3-(tetrahydropyran-4-yl)propionamide;  
(2*R*)-2-(4-Cyclobutanesulfonylphenyl)-*N*-pyrazin-2-yl-3-(tetrahydropyran-4-yl)propionamide;

(2*R*)-2-(4-Cyclobutanesulfonylphenyl)-*N*-(5-fluorothiazol-2-yl)-3-(tetrahydropyran-4-yl)propionamide;

(*E*)-2-(4-Cyclopropanesulfonylphenyl)-*N*-(5-fluorothiazol-2-yl)-3-(tetrahydropyran-4-yl)acrylamide;

(*E*)-*N*-(5-Fluorothiazol-2-yl)-2-(4-methanesulfonylphenyl)-3-(tetrahydropyran-4-yl)acrylamide;

(*E*)-2-(4-Methanesulfonylaminophenyl)-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylacrylamide;

2-[4-(Pyridin-3-ylsulfanyl)phenyl]-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-(4-Methoxymethanesulfonylphenyl)-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-[4-(Tetrahydropyran-4-sulfonyl)phenyl]-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-[4-(Pyridine-3-sulfonyl)phenyl]-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-(4-Cyclopropylmethanesulfonylphenyl)-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-[4-([1,2,4]Oxadiazol-3-ylmethanesulfonyl)phenyl]-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-[4-([1,3]Dioxolan-2-ylmethanesulfonyl)phenyl]-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-[4-(Oxetane-3-sulfonyl)phenyl]-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-[4-((3*S*)-Tetrahydrofuran-3-sulfonyl)phenyl]-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-[4-((3*R*)-Tetrahydrofuran-3-sulfonyl)phenyl]-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-(4-Cyclobutanesulfonylphenyl)-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-[4-(2-Oxopropane-1-sulfonyl)phenyl]-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-(4-Methylsulfamoylphenyl)-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-(4-Dimethylsulfamoylphenyl)-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-[4-(4-Methylpiperazine-1-sulfonyl)phenyl]-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-{4-[(Pyridin-2-ylmethyl)sulfamoyl]phenyl}-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-{4-[(Pyridin-3-ylmethyl)sulfamoyl]phenyl}-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-[4-(Azetidine-1-sulfonyl)phenyl]-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-(4-Cyclopropylsulfamoylphenyl)-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-[4-(Cyclopropylmethylsulfamoyl)phenyl]-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

3-(Tetrahydropyran-4-yl)-*N*-thiazol-2-yl-2-{4-[(thiophen-2-ylmethyl)sulfamoyl]phenyl}propionamide;

2-[4-((1*S*,4*S*)-2-Oxa-5-azabicyclo[2.2.1]heptane-5-sulfonyl)phenyl]-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-(4-Ethylsulfamoylphenyl)-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-[4-(4-Methyl-[1,4]diazepane-1-sulfonyl)phenyl]-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-[4-(Imidazole-1-sulfonyl)phenyl]-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

*N*-(5-Chlorothiazol-2-yl)-2-[4-(2-dimethylaminoethylsulfamoyl)phenyl]-3-(tetrahydropyran-4-yl)propionamide; and

*N*-(5-Chlorothiazol-2-yl)-2-[4-(piperazine-1-sulfonyl)phenyl]-3-(tetrahydropyran-4-yl)propionamide;

or a pharmaceutically acceptable salt thereof.

18. (cancelled) A compound selected from:

(2*R*)-2-(4-Cyclobutanesulfonylphenyl)-*N*-pyrazin-2-yl-3-(tetrahydropyran-4-yl)propionamide; and

(2*R*)-2-(4-Cyclobutanesulfonylphenyl)-*N*-(5-fluorothiazol-2-yl)-3-(tetrahydropyran-4-yl)propionamide;


or a pharmaceutically acceptable salt thereof.

19. (cancelled) (2*R*)-2-(4-Cyclopropanesulfonylphenyl)-*N*-(5-fluorothiazol-2-yl)-3-(tetrahydropyran-4-yl)propionamide, or a pharmaceutically acceptable salt thereof.

20. (cancelled) (2*R*)-2-(4-Cyclopropanesulfonylphenyl)-*N*-pyrazin-2-yl-3-(tetrahydropyran-4-yl)propionamide, or a pharmaceutically acceptable salt thereof.

21. (cancelled) (*E*)-*N*-(5-Fluorothiazol-2-yl)-2-(4-methanesulfonylphenyl)-3-(tetrahydropyran-4-yl)acrylamide, or a pharmaceutically acceptable salt thereof.

22. (cancelled) A compound of Formula (I):



(I)

or a pharmaceutically acceptable salt thereof, wherein:

Q is 4-tetrahydropyranyl;

T together with the  $-N=C-$  to which it is attached forms a 2-pyrazinyl or 2-thiazolyl ring;

$R^1$  and  $R^2$  are hydrogen;

$R^3$  and  $R^4$  each independently are hydrogen or fluoro;

$R^5$  is  $SO_2R^8$ , or  $SO_2NR^9R^{10}$ ;

$R^6$  is hydrogen;


$R^8$  is a  $C_{3-5}$ cycloalkyl group or a 4-6-membered heterocyclic group, and, in addition, when the dotted line together with the solid line forms a double bond  $R^8$  may be a  $C_{1-3}$ alkyl group;

$R^9$  and  $R^{10}$  are independently  $C_{0-4}$ alkyl, provided that  $R^9$  and  $R^{10}$  are not both hydrogen;

$m$  is 0; and

the dotted line together with the solid line forms an optional double bond, and  $\Delta$  indicates that the double bond has the (E)-configuration.

23. (cancelled) A compound of Formula (I):



(I)

or a pharmaceutically acceptable salt thereof, wherein:

Q is 4-tetrahydropyranyl;

T together with the  $-N=C-$  to which it is attached forms a 2-pyrazinyl or 2-thiazolyl ring;

$R^1$  and  $R^2$  are hydrogen;

$R^3$  and  $R^4$  each independently are hydrogen or fluoro;

$R^5$  is  $SO_2R^8$ ;

$R^6$  is hydrogen;

$R^8$  is a  $C_{3-4}$ cycloalkyl group and, in addition, when the dotted line together with the solid line forms a double bond  $R^8$  may be a  $C_{1-3}$ alkyl group;

$m$  is 0; and

the dotted line together with the solid line forms an optional double bond, and  $\Delta$  indicates that the double bond has the (E)-configuration.

24. (cancelled) A pharmaceutical composition comprising a compound according to claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.


25. (cancelled) A method of prophylactic or therapeutic treatment of a condition where activation of GK is desirable comprising a step of administering an effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt thereof.

26. (cancelled) A method of prophylactic or therapeutic treatment of hyperglycemia or diabetes comprising a step of administering an effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt thereof.


27. (cancelled) The method according to claim 26 wherein the compound according to any one of claim 1 is administered in combination with one or more other anti-hyperglycemic agents or anti-diabetic agents.

28. (cancelled) A method of prevention of diabetes in a human demonstrating pre-diabetic hyperglycemia or impaired glucose tolerance comprising a step of administering an effective prophylactic amount of a compound according to claim 1, or a pharmaceutically acceptable salt thereof.


29. (cancelled) A process for the preparation of a compound of Formula (Ia)



said process comprising a step of the condensation of a compound of Formula (IV):




with a compound of Formula (V):




wherein  $\text{Q}$ ,  $\text{T}$ ,  $\text{R}^1$  to  $\text{R}^6$ ,  $\text{m}$  and  $\Delta$  are as defined in claim 1.

30. (cancelled) A process for the preparation of a compound of Formula (Ib)




(Ib)

said process comprising a step of the condensation of a compound of Formula (VIII):




VIII

with a compound of Formula (V):



wherein Q, T, R<sup>1</sup> to R<sup>6</sup> and m are as defined in claim 1.

31. (cancelled) A compound of formula (IV):



wherein Q is 4-tetrahydropyranyl;

R<sup>1</sup> and R<sup>2</sup> are hydrogen;

R<sup>5</sup> is SO<sub>2</sub>R<sup>8</sup>, or SO<sub>2</sub>NR<sup>9</sup>R<sup>10</sup>;

R<sup>6</sup> is hydrogen;

R<sup>8</sup> is a C<sub>1-3</sub>alkyl group, a C<sub>3-5</sub>cycloalkyl group or a 4-6-membered heterocyclic group;

R<sup>9</sup> and R<sup>10</sup> are independently C<sub>0-4</sub>alkyl, provided that R<sup>9</sup> and R<sup>10</sup> are not both hydrogen;


m is 0; and

the dotted line together with the solid line forms a double bond, and  $\Delta$  indicates that the double bond has the (*E*)-configuration.

32. (cancelled) A compound of Formula (IV) selected from:

(*E*)-2-(4-Cyclopropanesulfonylphenyl)-3-(tetrahydropyran-4-yl)acrylic acid;  
(*E*)-2-(4-Cyclopropanesulfinylphenyl)-3-(tetrahydropyran-4-yl)acrylic acid;  
(*E*)-2-(4-Methanesulfonylphenyl)-3-(tetrahydropyran-4-yl)acrylic acid;  
(*E*)-2-(4-Ethanesulfonylphenyl)-3-(tetrahydropyran-4-yl)acrylic acid; and  
(*E*)-2-[4-(Propane-1-sulfonyl)phenyl]-3-(tetrahydropyran-4-yl)acrylic acid.

33. (cancelled) A compound of formula (VIII):



Q is 4-tetrahydropyranyl;

R<sup>1</sup> and R<sup>2</sup> are hydrogen;

R<sup>5</sup> is SO<sub>2</sub>R<sup>8</sup>, or SO<sub>2</sub>NR<sup>9</sup>R<sup>10</sup>;

R<sup>6</sup> is hydrogen;

R<sup>8</sup> is a C<sub>3-5</sub>cycloalkyl group or a 4-6-membered heterocyclic group;

R<sup>9</sup> and R<sup>10</sup> are independently C<sub>0-4</sub>alkyl, provided that R<sup>9</sup> and R<sup>10</sup> are not both hydrogen; and


m is 0.

34. (cancelled) A compound of Formula (VIII) selected from:

2-(4-Cyclopropanesulfonylphenyl)-3-(tetrahydropyran-4-yl)-propionic acid;  
2-(4-Methoxymethanesulfanylphenyl)-3-(tetrahydropyran-4-yl)-propionic acid;  
2-(4-Ethylsulfamoylphenyl)-3-(tetrahydropyran-4-yl)propionic acid;  
2-(4-Cyclobutanesulfonylphenyl)-3-(tetrahydropyran-4-yl)propionic acid;  
(2*R*)-2-(4-Cyclopropanesulfonylphenyl)-3-(tetrahydropyran-4-yl)propionic acid;  
(2*R*)-2-(4-Ethylsulfamoylphenyl)-3-(tetrahydropyran-4-yl)propionic acid; and  
(2*R*)-2-(4-Cyclobutanesulfonylphenyl)-3-(tetrahydropyran-4-yl)propionic acid.

35. (cancelled) 5-Fluorothiazol-2-ylamine or an amide or acid addition salt thereof.

36. (newly presented) A compound of Formula (I):



(I)

or a pharmaceutically acceptable salt thereof, wherein:

Q is 4-tetrahydropyranyl;

T together with the  $-N=C-$  to which it is attached forms a 2-pyrazinyl or 2-thiazolyl ring;

R<sup>1</sup> and R<sup>2</sup> are hydrogen;

R<sup>3</sup> and R<sup>4</sup> each independently are hydrogen or fluoro;

R<sup>5</sup> is SO<sub>2</sub>R<sup>8</sup>;

R<sup>6</sup> is hydrogen;

$R^8$  is a  $C_{3-4}$ cycloalkyl group and, in addition, when the dotted line together with the solid line forms a double bond  $R^8$  may be a  $C_{1-3}$ alkyl group;

m is 0; and

the dotted line together with the solid line forms an optional double bond, and  $\Delta$  indicates that the double bond has the (*E*)-configuration.


37. (newly presented) A compound according to claim 36, or a pharmaceutically acceptable salt thereof, wherein the dotted line together with the solid line forms a double bond.

38. (newly presented) A compound according to claim 36, or a pharmaceutically acceptable salt thereof, wherein the dotted line together with the solid line forms a single bond.

39. (newly presented) A compound according to claim 38, or a pharmaceutically acceptable salt thereof, wherein the dotted line together with the solid line forms a single bond, and the absolute configuration at the asymmetric centre  $\alpha$  to the amide carbonyl carbon is (*R*).

40. (newly presented) A compound according to claim 36, or a pharmaceutically acceptable salt thereof, wherein  $R^3$  is fluoro or hydrogen and  $R^4$  is hydrogen.

41. (newly presented) A compound according to claim 36, or a pharmaceutically acceptable salt thereof, wherein the group of formula




is 2-thiazolyl;

R<sup>3</sup> is 5-fluoro; and

$R^4$  is hydrogen.

42. (newly presented) A compound according to claim 36, or a pharmaceutically acceptable salt thereof, wherein the group of formula



is 2-pyrazinyl;

$R^3$  is hydrogen; and

$R^4$  is hydrogen.

43. (newly presented) A compound according to claim 36, or a pharmaceutically acceptable salt thereof, wherein  $R^5$  is  $SO_2C_{3-4}$ cycloalkyl.

44. (newly presented) A compound selected from:

2-(4-cyclopropanesulfonylphenyl)-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

2-(4-cyclopropanesulfonylphenyl)-*N*-(5-fluorothiazol-2-yl)-3-(tetrahydropyran-4-yl)propionamide;

2-(4-cyclopropanesulfonylphenyl)-*N*-pyrazin-2-yl-3-(tetrahydropyran-4-yl)propionamide;

(*E*)-2-(4-cyclopropanesulfonylphenyl)-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylacrylamide;

(*E*)-2-(4-methanesulfonylphenyl)-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylacrylamide;

(2*R*)-3-(tetrahydropyran-4-yl)-2-(4-methanesulfonylphenyl)-*N*-thiazol-2-ylpropionamide;

(2*R*)-2-(4-cyclopropanesulfonylphenyl)-*N*-(5-fluorothiazol-2-yl)-3-(tetrahydropyran-4-yl)propionamide;

(2*R*)-2-(4-cyclopropanesulfonylphenyl)-*N*-pyrazin-2-yl-3-(tetrahydropyran-4-yl)propionamide;

(2*R*)-2-(4-cyclopropanesulfonylphenyl)-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

(2*R*)-2-(4-cyclobutanesulfonylphenyl)-*N*-pyrazin-2-yl-3-(tetrahydropyran-4-yl)propionamide;

• (2*R*)-2-(4-cyclobutanesulfonylphenyl)-*N*-(5-fluorothiazol-2-yl)-3-(tetrahydropyran-4-yl)propionamide;

(*E*)-2-(4-cyclopropanesulfonylphenyl)-*N*-(5-fluorothiazol-2-yl)-3-(tetrahydropyran-4-yl)acrylamide;

(*E*)-*N*-(5-fluorothiazol-2-yl)-2-(4-methanesulfonylphenyl)-3-(tetrahydropyran-4-yl)acrylamide;

(*E*)-*N*-(5-fluorothiazol-2-yl)-2-[4-(propane-1-sulfonyl)phenyl]-3-(tetrahydropyran-4-yl)acrylamide;

2-(4-cyclobutanesulfonylphenyl)-3-(tetrahydropyran-4-yl)-*N*-thiazol-2-ylpropionamide;

or a pharmaceutically acceptable salt thereof.

45. (newly presented) A compound consisting of (2*R*)-2-(4-cyclopropanesulfonylphenyl)-*N*-(5-fluorothiazol-2-yl)-3-(tetrahydropyran-4-yl)propionamide, or a pharmaceutically acceptable salt thereof.

46. (newly presented) A compound consisting of (2*R*)-2-(4-cyclopropanesulfonylphenyl)-*N*-pyrazin-2-yl-3-(tetrahydropyran-4-yl)propionamide, or a pharmaceutically acceptable salt thereof.

47. (newly presented) A pharmaceutical composition comprising a compound according to claim 36, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.


48. (newly presented) A method of prophylactic or therapeutic treatment of a condition where activation of GK is desirable comprising a step of administering an effective amount of a compound according to claim 36, or a pharmaceutically acceptable salt thereof.

49. (newly presented) A method of prophylactic or therapeutic treatment of hyperglycemia or diabetes comprising a step of administering an effective amount of a compound according to claim 36, or a pharmaceutically acceptable salt thereof.

50. (newly presented) The method according to claim 49 wherein the compound according to claim 36 is administered in combination with one or more other anti-hyperglycemic agents or anti-diabetic agents.


51. (newly presented) A method of prevention of diabetes in a human demonstrating pre-diabetic hyperglycemia or impaired glucose tolerance comprising a step of administering an effective prophylactic amount of a compound according to claim 36, or a pharmaceutically acceptable salt thereof.

52. (newly presented) A process for the preparation of a compound of Formula (Ia)




(Ia)

said process comprising a step of the condensation of a compound of Formula (IV):




with a compound of Formula (V):




wherein Q, T, R<sup>1</sup> to R<sup>6</sup>, m and Δ are as defined in claim 36.


53. (newly presented) A process for the preparation of a compound of Formula (Ib)



said process comprising a step of the condensation of a compound of Formula (VIII):




with a compound of Formula (V):



wherein Q, T, R<sup>1</sup> to R<sup>6</sup> and m are as defined in claim 36.

54. (newly presented) A compound of formula (IV):



wherein Q is 4-tetrahydropyranyl;

R<sup>1</sup> and R<sup>2</sup> are hydrogen;

R<sup>5</sup> is SO<sub>2</sub>R<sup>8</sup>;

R<sup>6</sup> is hydrogen;

R<sup>8</sup> is a C<sub>3-4</sub>cycloalkyl group or a C<sub>1-3</sub>alkyl group;

m is 0; and

Δ indicates that the double bond has the (E)-configuration.


55. (newly presented) A compound according to claim 54, selected from:

(E)-2-(4-cyclopropanesulfonylphenyl)-3-(tetrahydropyran-4-yl)acrylic acid;

(E)-2-(4-methanesulfonylphenyl)-3-(tetrahydropyran-4-yl)acrylic acid; and

(E)-2-[4-(propane-1-sulfonyl)phenyl]-3-(tetrahydropyran-4-yl)acrylic acid.

56. (newly presented) A compound of formula (VIII):



wherein Q is 4-tetrahydropyranyl;

R<sup>1</sup> and R<sup>2</sup> are hydrogen;

R<sup>5</sup> is SO<sub>2</sub>R<sup>8</sup>;

R<sup>6</sup> is hydrogen;

R<sup>8</sup> is a C<sub>3-4</sub>cycloalkyl group; and

m is 0.

57. (newly presented) A compound according to claim 56 of Formula (VIII) selected from:

2-(4-cyclopropanesulfonylphenyl)-3-(tetrahydropyran-4-yl)propionic acid;

2-(4-cyclobutanesulfonylphenyl)-3-(tetrahydropyran-4-yl)propionic acid;

(2*R*)-2-(4-cyclopropanesulfonylphenyl)-3-(tetrahydropyran-4-yl)propionic acid;

and

(2*R*)-2-(4-cyclobutanesulfonylphenyl)-3-(tetrahydropyran-4-yl)propionic acid.

58. (newly presented) A compound consisting of 5-fluorothiazol-2-ylamine or an amide or acid addition salt thereof.